Experts highlight their choice of key studies being presented at the 2023 ASCO Annual Meeting. CCO’s Independent Conference Coverage will include timely summaries, expert analysis, and practical implications of the latest research and developments in oncology to help you stay at the forefront of advances in cancer care.
Released: June 01, 2023
Share
Erika P. Hamilton, MD
Director, Breast Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute
Nashville, Tennessee
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota
Christopher H. Lieu, MD
Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado
Jason Luke, MD, FACP
Associate Director for Clinical Research
Director, Immunotherapy and Drug Development Center
Associate Professor of Medicine
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, Pennsylvania
Lauren Prescott, MD, MPH
Associate Professor of Gynecologic Oncology
Department of Obstetrics and Gynecology
Vanderbilt University Medical Center
Nashville, Tennessee
Karen Reckamp, MD, MS
Director, Division of Medical Oncology
Associate Director, Clinical Research
Professor, Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, California
Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California
Jeffrey P. Sharman, MD
Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon
Rachna Shroff, MD, MS, FASCO
Interim Executive Council Member, Clinical Affairs for the University of Arizona Cancer Center
Chief, Division of Hematology/Oncology, UA COM-T
Associate Director of Clinical Investigations, UACC
Professor of Medicine
University of Arizona College of Medicine
Tucson, Arizona
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts
Heather Wakelee, MD, FASCO
Professor of Medicine
Department of Medicine/Oncology
Stanford University
Stanford University Cancer Institute
Stanford, California
Eunice S. Wang, MD
Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Jeffrey S. Weber, MD, PhD
Professor of Medicine
NYU Grossman School of Medicine
Deputy Director
NYU Langone Health
Laura and Isaac Perlmutter Cancer Center
New York, New York
Provided by Clinical Care Options, LLC
Primary Author
Erika P. Hamilton, MD
Director, Breast Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute
Nashville, Tennessee
Erika Hamilton, MD: consultant/advisor: Arcus, AstraZeneca, Daiichi Sankyo, Ellipses Pharma, Greenwich LifeSciences, iTeos, Janssen, Lilly, Loxo, Mersana, Novartis, Olema Pharmaceuticals, Orum Therapeutics, Pfizer, Relay Therapeutics, Roche/Genentech, Seagen, Stemline Therapeutics, Tubulis, Verascity Science; researcher (paid to institution): AbbVie, Acerta Pharma, Accutar Biotechnology, ADC Therapeutics, Akesobio Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss Biopharmaceuticals, Boehringer Ingelheim, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan-Florentine, Curis, CytomX, Daiichi Sankyo, Dana Farber Cancer Inst, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Ellipses Pharma, Elucida Oncology, EMD Serono, FujiFilm, G1 Therapeutics, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind Pharmaceuticals, Leap Therapeutics, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Novartis, Nucana, Olema, OncoMed, Onconova Therapeutics, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, Seagen, Sermonix Pharmaceuticals, Shattuck Labs, StemCentRx, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics, Verastem, Zenith Epigenetics, Zymeworks.
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota
Shaji Kumar, MD: consultant/advisor: AbbVie, Amgen, Antengene, Arcellx, AstraZeneca, BeiGene, Bluebird Bio, Bristol Myers Squibb, Janssen, Roche-Genentech, K36, Loxo Oncology, Oncopeptides, Pfizer, Sanofi, Secura Biotherapeutics, Takeda; researcher: AbbVie, Allogene, Amgen, AstraZeneca, Bristol Myers Squibb, Carsgen, GSK, Janssen, Regeneron, Roche-Genentech, Takeda.
Christopher H. Lieu, MD
Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado
Christopher H. Lieu, MD: researcher: Merck.
Jason Luke, MD, FACP
Associate Director for Clinical Research
Director, Immunotherapy and Drug Development Center
Associate Professor of Medicine
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, Pennsylvania
Jason Luke, MD, FACP: consultant/advisor/speaker: 7 Hills, AbbVie, Actym, Affivant, Agenus, Alnylam, Alphamab Oncology, Arch Oncology, Atomwise, Bayer, BioCytics, Bright Peak, Bristol Myers Squibb, Castle, Checkmate, Codiak, Crown, Cugene, Curadev, Day One, Duke Street Bio, EMD Serono, Eisai, Endeavor, Exo, Flame, Fstar, G1 Therapeutics, Genentech, Gilead, Glenmark, HotSpot, IO Biotech, Ikena, Immatics, Immunocore, Incyte, Instil, Inzen, Janssen, KSQ, Kadmon, Kanaph, Macrogenics, Mavu, Merck, Mersana, Nektar, NeoTx, Novartis, Onc.AI, OncoNano, Partner, Pfizer, Pioneering Medicines, physIQ, PsiOxus, Pyxis, RefleXion, Regeneron, Replimmune, Ribon, Roivant, STINGthera, STipe, Saros, Servier, Synlogic, Synthekine, Tempest, Xilio; research support (paid to institution): AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Numab, Palleon, Pfizer, Replimune, Rubius, Servier, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, Xencor; data safety monitoring board: AbbVie, Agenus, Immutep, Evaxion; royalties or patent beneficiary (both provisional): serial #15/612,657 (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof); individual publicly traded stocks and stock options: Actym, Alphamab Oncology, Arch Oncology, Duke Street Bio, Kanaph, Mavu, NeoTx, Onc.AI, OncoNano, physIQ, Pyxis, Saros, STipe, Tempest; consultant: AbbVie, Agenus, Alnylam, Atomwise, Bayer, Bristol Myers Squibb, Castle, Checkmate, Codiak, Crown, Cugene, Curadev, Day One, Eisai, EMD Serono, Endeavor, Flame, G1 Therapeutics, Genentech, Gilead, Glenmark, HotSpot, Kadmon, KSQ, Janssen, Ikena, Inzen, Immatics, Immunocore, Incyte, Instil, IO Biotech, Macrogenics, Merck, Mersana, Nektar, Novartis, Partner, Pfizer, Pioneering Medicines, PsiOxus, Regeneron, Replimune, Ribon, Roivant, Servier, STINGthera, Synlogic, Synthekine.
Lauren Prescott, MD, MPH
Associate Professor of Gynecologic Oncology
Department of Obstetrics and Gynecology
Vanderbilt University Medical Center
Nashville, Tennessee
Lauren Prescott, MD, has no relevant financial relationships to disclose.
Karen Reckamp, MD, MS
Director, Division of Medical Oncology
Associate Director, Clinical Research
Professor, Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, California
Karen Reckamp, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Blueprint, Daiichi Sankyo, EMD Serono, Genentech, GSK, Janssen, Lilly, Mirati; research funding (paid to institution): Blueprint, Calithera, Daiichi Sankyo, Elevation, Genentech, Janssen.
Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California
Ritu Salani, MD, MBA: consultant/advisor/speaker: GSK, Merck, Regeneron, Seagen.
Jeffrey P. Sharman, MD
Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon
Jeffrey P. Sharman, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Janssen, Lilly, Merck.
Rachna Shroff, MD, MS, FASCO
Interim Executive Council Member, Clinical Affairs for the University of Arizona Cancer Center
Chief, Division of Hematology/Oncology, UA COM-T
Associate Director of Clinical Investigations, UACC
Professor of Medicine
University of Arizona College of Medicine
Tucson, Arizona
Rachna T. Shroff, MD, MS: consultant/advisor/speaker: Astellas, AstraZeneca, Boehringer Ingelheim, Clovis, Genentech, Incyte, Merck, QED, Servier, Syros, Taiho, Zymeworks; researcher: Bayer, Bristol Myers Squib, IMV, Loxo, Merck, Novocure, NuCana, Pieris, QED, Rafael, Seagen, Taiho.
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts
Sara Tolaney, MD, MPH: consultant/advisor: 4D Pharma, Aadi Biopharma, ARC Therapeutics, Artios Pharma, AstraZeneca, Bayer, BeyondSpring Pharmaceuticals, Blueprint Medicines, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Eisai, Ellipses Pharma, Genentech/Roche, Gilead, Incyte Corp, Infinity Therapeutics, Jazz Pharmaceuticals, Lilly, Menarini/Stemline, Merck, Myovant, Novartis, OncoSec Medical Inc., OncXerna, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Umoja Biopharma, Zentalis, Zetagen, Zymeworks; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Gilead, Gilead, Lilly, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer, Seattle Genetics.
Heather Wakelee, MD, FASCO
Professor of Medicine
Department of Medicine/Oncology
Stanford University
Stanford University Cancer Institute
Stanford, California
Heather Wakelee, MD, FASCO: consultant/advisor/speaker: Mirati; researcher: AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Genentech/Roche, Helsinn, Merck, SeaGen, Xcovery.
Eunice S. Wang, MD
Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Amgen, Astellas, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genentech, Gilead, GlaxoSmithKline, Janssen, Jazz, Kite, Kura Oncology, Mana Therapeutics, Novartis, Pfizer, PharmaEssentia, NuProbe, Rafael, Stemline, Takeda.
Jeffrey S. Weber, MD, PhD
Professor of Medicine
NYU Grossman School of Medicine
Deputy Director
NYU Langone Health
Laura and Isaac Perlmutter Cancer Center
New York, New York
Jeffrey S. Weber, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Incyte, Merck, Moderna, Pfizer, Regeneron.